OralCDx

About CDx Diagnostics

CDx Diagnostics is a commercial-stage diagnostics company specializing in AI-powered early cancer detection. Its flagship product, WATS 3D, is an adjunctive test for esophageal precancer that combines enhanced tissue sampling with a neural network for analysis and 3D imaging, recently receiving FDA Breakthrough Device Designation. The company targets the significant market for Barrett's esophagus surveillance, aiming to improve patient outcomes and reduce healthcare costs by catching dysplasia earlier than standard biopsies. It operates as a private company, generating revenue through its diagnostic testing services.

Therapeutic Areas